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WE investigated the serum concentration of vascular
endothelial growth factor (VEGF) and its two soluble
receptors, sVEGFR-1 and sVEGFR-2, in a group of 60
patients with systemic lupus erythematosus (SLE),
and 20 healthy controls, using an enzyme-linked
immunosorbent assay. We examined a possible asso-
ciation between serum levels of these proteins and
certain clinical and laboratory parameters as well as
SLE activity. VEGF, sVEGFR-1 and sVEGFR-2 were
detectable in all patients with SLE and in all normal
individuals. The VEGF level was higher in active SLE
(mean, 300.8 pg/ml) than in inactive SLE (mean,
165.9 pg/ml) (p B/0.05) or in the control group
(mean, 124.7 pg/ml) (p B/0.04). The highest
sVEGFR-1 concentrations were also detected in active
SLE patients (mean, 42.2 pg/ml) and the lowest in
inactive disease (mean, 32.0 pg/ml) (p B/0.01). In
contrast, the levels of sVEGFR-2 were lower in SLE
(mean, 12557.6 pg/ml) than in the control group
(mean, 15025.3 pg/ml) (p B/0.05). We found a posi-
tive correlation between sVEGFR-1 concentration and
the SLE activity score r/0.375 (p B/0.004) and a
negative, but statistically insignificant correlation
between sVEGFR-2 and SLE activity (r//0.190,
p  /0.05). Treatment with steroids and cytotoxic
agents did not influence VEGF or its soluble receptors
levels. In conclusion, in SLE patients the levels of
VEGF and sVEGFR-1 are higher in patients with active
SLE than in inactive disease or healthy persons. In
contrast, the level of sVEGFR-2 is lower in active SLE
than in inactive disease. The imbalance between
VEGF and its soluble receptors may be important in
SLE pathogenesis.
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Introduction
Vascular endothelial growth factor (VEGF) is a key
regulator of vasculogenesis and angiogenesis.
1,2
VEGF is produced by endothelial cells, macrophages,
fibroblasts and smooth muscle cells.
1 It is a chimeric
glycoprotein with a molecular weight of 34/45 kDa,
consisting of two subunits.
3,4 Five isoforms of human
VEGF have been described to date, each generated
by alternative splicing of a single mRNA and resulting
in proteins of varying amino acid length,
(VEGF).
121,145,165,189,206 This angiogenic cytokine
binds to receptors on endothelial cells and acts as
direct inducer of angiogenesis both in vivo and in
vitro.
5 The two best characterised VEGF receptors
are termed VEGF receptor 1 (VEGFR-1) and VEGF
receptor 2 (VEGFR-2). VEGFR-1 (fms-like tyrosine
kinase 1) and VGFR-2 (kinase domain receptor/
FLK-1) are specific tyrosine kinase receptors that
together with platelet-derived growth factor re-
ceptors form the subtype III of tyrosine kinase
receptors.
2,68 The gene for VEGFR-1 is almost
exclusively expressed on endothelial cells but is
also found on monocytes.
9 VEGFR-2 is not found
on monocytes. Both receptors share common fea-
tures such as seven immunglobulin-like extracellular
domains, a single transmembrane region and a
consensus tyrosine kinase sequence interrupted by
a kinase insert domain, and they are highly glycosy-
lated.
10,11 However, although VEGFR-1 binds to
VEGF with substantially higher affinity, most of the
biological effects of VEGF seem to be mediated via
VEGFR-2.
12
Recently, a naturally occurring soluble form of
VEGFR-1 (sVEGFR-1) has been identified, but natu-
rally occurring secreted forms of sVEGFR-2 have not
been reported to date.
11,1315 The physiological role
of sVEGFR-1 and sVEGFR-2 is still undetermined. It
has been shown that sVEGFR-1 retains its high-
affinity binding to VEGF and it is likely to be a
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293negative regulator of VEGF availability, or that it may
prolong the different VEGF activities.
13,1618
Angiogenic cytokines and angiogenesis inhibitors
play an important role in the pathogenesis of several
diseases including connective tissue diseases.
1922 In
our previous studies we have shown that in SLE
patients the serum level of some angiogenic cyto-
kines is higher than in healthy controls, but the level
of endostatin, the endogenous angiogenesis inhibi-
tor, is similar in SLE and in the control group.
21,22
Moreover, selected pro-angiogenic cytokines corre-
lated with SLE activity.
In the present study we measured the serum
concentrations of VEGF and its soluble receptors
VEGFR-1 and VEGFR-2 in patients with SLE using an
enzyme-linked immunosorbent assay. The serum
levels of these proteins were also correlated with
disease activity and some clinical and laboratory
parameters. To the best of our knowledge, the serum
levels of sVEGFR-1 and sVEGFR-2 in patients with
SLE have not been investigated to date.
Patients and methods
The study group consisted of 60 patients with SLE (55
females and five males) and 20 sex-matched and age-
matched healthy volunteers. The median age of the
SLE patients was 41 years (range, 18/75 years). The
diagnosis of SLE was based on the revised criteria of
the American Rheumatism Association.
23 The mean
duration of the disease was 71 months (range, 3
months/24 years). Twenty-four patients were never
treated with steroids or any other immunosuppres-
sive agents. Fourteen patients were treated with
prednisone at a dose of 5/20 mg/day during the
study and five patients with prednisone and azatiopr-
ine or cyclophosphamide. Patients’ histories were
recorded and physical examination was performed
on the day of blood collection. Patients with both
active and inactive disease were included in the
study. In all patients the activity of the disease was
determined according to the systemic lupus activity
measure (SLAM) scale.
24 Each patient was examined
on two separate occasions 2/4 weeks apart. The
SLAM system includes 24 clinical manifestations and
eight laboratory parameters. The maximum score in
this system is 84 points. In our group of patients, the
number of points ranged from 9 to 27. In the present
study we considered a score of 0/15 points as
inactive disease and a score over 15 points as active
disease. By this definition active disease was found in
32 patients and 28 patients had inactive disease.
The clinical and laboratory features of SLE patients
are presented in Table 1. A control group of 20
healthy volunteers (17 women and three men) aged
from 35 to 58 years (median, 45 years) was also
studied. Each person underwent a thorough physical
evaluation by one of the authors (E.R.). The patients
with SLE and controls showed no clinical signs of
infections or neoplastic disease and were not given
antibiotics or any other antibacterial or antiviral
medication for at least 4 weeks prior to blood
donation. This project was performed in accordance
with the Helsinki Declaration and was approved by
the local Ethics Committee. Informed consent was
obtained from all the patients.
Laboratory tests
In the study group the following laboratory para-
meters were analysed: complete blood cell count,
erythrocyte sedimentation rate (ESR), urinalysis,
blood urea nitrogen and creatinine levels, fibrinogen,
partial thromboblastin time, alanine aminotransferase
(ALT), asparate aminotransferase (AST), bilirubin,
immunoglobulins (IgG, IgM and IgA) and comple-
ment (C3,C 4) levels and antinuclear antibodies.
Immunoglobulin deposits at the dermal/epidermal
junction (lupus band test) were also determined.
Serum sampling and detection of VEGF and its
soluble receptors
Venous blood (5 ml) was collected in pyrogen-free
tubes, allowed to dot at 48C for 1 h and centrifuged at
2000 g for 10 min. The sera obtained were allocated
Table 1. Clinical and laboratory characteristics of SLE
patients
Symptoms Number of
patients
%
Total 60 100
Age (years) [mean
(range)]
41 (18/79)
Sex (male/female) 5/55 8.3/91.7
Active/inactive 32/28 53.3/46.7
Fever 15 25.0
Arthritis 54 90.0
Skin symptoms 30 50.0
Reticuloendothelial system
involvment
32 53.3
Renal disorder (kreatinine
 /1.3 mg/dl)
5 8.3
Neurologic symptoms 35 58.3
Antinuclear antibodies 49 81.6
Immunoglobulins deposit at
the dermal/epidermal junction
33 55
Anaemia (haemoglobin
B/12 g/dl)
30 50.0
Leukopaenia (white blood cells
B/3.5/10
9/l)
20 33.3
Thrombocytopaenia (platelets
B/150/10
9/l)
14 23.3
C-reactive protein
( /4.7 mg/L)
15 25.0
Raised ESR ( /25 mm/h) 24 41.6
Treatment with steroids
during the study
14 23.3
Treatment with steroids and
cytoxic agents during the study
5 8.3
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for VEGF and its soluble receptors. The serum was
randomly coded and the testing was carried out
without knowledge of the clinical status of the subject
or of any related laboratory data. The cytokines
serum concentrations were assayed by specific,
commercially available, enzyme-linked immunosor-
bent assay kits (Qantikine; R&D Systems Inc., Min-
neapolis, Minnesota, USA) using horseradish
peroxidase detection in accordance with the manu-
facturer’s instructions. The absorption was red at 492
nm. In each assay the appropriate recombinant
human cytokine or receptor was used to generate
the standard curve. Standards as well as samples
were assayed as duplicates and the inter-assay
variations were shown to be with the range given
by the manufacturer. The procedure has previously
been described in detail.
22,25 The sensitivity of the
assay for VEGF was B/5.0 pg/ml with intra-assay and
inter-assay coefficients of variation of 5.1% (n/20)
and 6.2% (n/40) at 0.9 ng/ml and 1.0 ng/ml. The
mean minimum detectable dose of VEGFR-1 was 5.01
pg/ml and ranged from 1.63/14.4 pg/ml, with intra-
assay and inter-assay coefficients of variation of 3.5%
(n/20) and 8.1% (n/40) at 1.5 ng/ml. Serum for
the sVEGFR-2 concentration measurement was di-
luted five-fold. The mean value of minimum detect-
able dose was 4.6 pg/ml (range, 1.0/11.4 pg/ml)
with intra-assay and inter-assay coefficients of varia-
tion of 2.9% (n/20) and 5.7% (n/40) at 2.9 ng/ml.
The concentrations of VEGF and soluble VEGF
receptors in the samples were determined by inter-
polation from the standard curve.
Statistical analysis
For the statistical analysis of the data the range of
measured variable is given (minimum/maximum).
The mean arithmetic value, median and standard
deviation were also calculated. The medians were
compared using the Mann/Whitney test and the
Kruskal/Wallis test. The correlation between features
was evaluated using the Spearman rank coefficient p.
Comparisons and correlations were considered sig-
nificant when pB/0.05.
Results
In the group of 60 SLE patients, 32 were with active
and 28 with inactive disease according to the Liang et
al. scoring system.
24 The serum concentrations of
VEGF and its soluble receptors sVEGFR-1 and
sVEGFR-2 were detectable in all SLE patients and in
healthy volunteers. The results are presented in Table
2. The highest VEGF concentration was found in
patients with active SLE (mean, 234.2 pg/ml) and the
lowest in the healthy control group (124.7 pg/ml)
(pB/0.04). No difference in VEGF serum concentra-
tions in inactive SLE compared with normal indivi-
duals was observed. The serum level of VEGF was
significantly higher in patients with active disease as
compared with patients with inactive SLE (Table 2).
The highest sVEGFR-1 concentrations were also
detected in active SLE patients (mean, 42.4 pg/ml)
and the lowest in inactive SLE patients (mean, 32.0
pg/ml) (pB/0.01). The level of this soluble receptor
in inactive SLE and in healthy individuals were not
statistically different. In contrast, the levels of
sVEGFR-2 in active and inactive SLE patients were
similar (Table 2). However, the concentrations of this
receptor in SLE patients were lower (mean, 12.5 ng/
ml) than in the control group (mean, 15.0 ng/ml)
(pB/0.05). We found a positive correlation between
sVEGFR-1 concentration and the SLE activity score
(r/0.375, pB/0.004) and a negative but statistically
not significant correlation between sVEGFR-2 and
SLE activity (Fig. 1).
We analysed the correlation between serum levels
of VEGF and sVEGFR-1 (r/0.166), VEGF and
sVEGR-2 (r//0.053) as well as sVEGFR-1 and
sVEGFR-2 (r/0.043). However, the differences were
not statistically significant (pB/0.05) (data not
shown).
Table 2. Serum levels of VEGF and its soluble receptors (sVEGFR-1 and sVEGFR-2) in patients with SLE and control group
Cytokine/receptors All SLE
(n/60) (a)
Active SLE
(n/32) (b)
Inactive SLE
(n/28) (c)
Control group
(n/20) (d)
Statistically significant
comparison
VEGF (pg/ml)
x9 /SD 234.29 /209.9 300.89 /250.9 165.39 /153.4 124.79 /59.7 (b)/(c)/(d), p/0.05
Median 150.4 202.4 116.1 123.5 (b)/(c), pB/0.05
Range 6.4/920.4 8.5/920.4 6.4/602.4 21.1/218.5 (b)/(d), pB/0.04
sVEGFR-1 (pg/ml)
x9 /SD 37.59 /14.5 42.49 /16.1 32.09 /10.1 38.39 /12.5 (b)/(c)/(d), pB/0.03
Median 36.3 39.5 31.2 38.25 (b)/(c), pB/0.01
Range 9.9/88.2 9.9/88.2 13.8/49.7 18.8/61.2
sVEGFR-2 (ng/ml)
x9 /SD 12.59 /3.6 12.09 /3.6 13.29 /3.6 15.09 /5.0 (a)/(d), pB/0.05
Median 12.0 11.7 12.7 14.2 (b)/(d), pB/0.04
Range 5.0/23.2 5.0/19.8 7.9/23.2 8.7/26
x9 /SD, Mean9 /standard deviation.
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level of VEGF and its soluble receptors with selected
clinical and laboratory parameters of the patients
with SLE. In the group of 60 patients, 14 were treated
with steroids and five with cytotoxic agents. How-
ever, the levels of VEGF, sVEGFR-1 and sVEGFR-2
were similar in both groups (p /0.05) (data not
shown). In contrast, the serum concentration of
VEGF was higher in the patients with immunoglobu-
lin deposit at the dermal/epidermal junction (mean,
288.6 pg/ml) than in the patients without this
symptom (mean, 162.2 pg/ml) (pB/0.02). The level
of sVEGFR-2 was also higher in SLE patients with skin
immunoglobulin deposits (mean, 13.2 ng/ml) than in
the patients without these deposits (mean, 11.7 ng/
ml) (pB/0.04). In contrast, sVEGFR-1 was similar in
both groups (mean, 38.4 pg/ml and 36.2 pg/ml,
respectively; p /0.05). The mean concentration of
sVEGFR-1 was higher in SLE patients with anaemia
(haemoglobinB/12 g/dl) at 43.3 pg/ml than in the
patients with haemoglobin concentration /12.0 g/dl
(31.9 pg/ml) (pB/0.001). In contrast, the levels of
VEGF and sVEGFR-2 were similar in both groups
(p /0.05). The VEGF and VEGFR-1 serum levels
were higher in the SLE patients with a high C-reactive
protein level (CRP) ( /4.7 mg/l) (mean values, 361.0
pg/ml and 44.1 pg/ml, respectively) than among
patients with a low CRP (B/4.7 mg/l) (192.2 pg/ml
and 35.2 pg/ml, respectively) (pB/0.02 and p B/0.01,
respectively). The level of sVEGFR-2 was similar in
both groups (p /0.05). We also analysed the rela-
tionship between VEGF, sVEGFR-1 and sVEGFR-2
serum levels in the patients with and without skin
symptoms, neurological symptoms, renal disorders
(kreatinine /1.3 mg/dl), fever, arthritis, antinuclear
antibodies, raised ESR ( /25 mm/h) and thrombocy-
topaenia (plateletsB/150/10
9/l). We found no sta-
tistically significant differences in the levels of these
cytokines or receptors in particular groups of pa-
tients.
Discussion
The results of numerous studies indicate that VEGF is
one of the main positive regulators of angiogenesis.
We have shown previously that in patients with active
SLE the serum concentration of this cytokine is higher
than in healthy controls or patients with inactive
disease.
21 We have also observed a positive but not
statistically significant correlation between the VEGF
concentration and the concentration of angiogenesis-
negative regulator (i.e. endostatin).
22 In these studies
we have been the first to evaluate serum concentra-
tions of VEGF soluble receptors (sVEGFR-1 and
sVEGFR-2) in SLE patients and the relationship
between these factors as well as their associations
with SLE activity and some SLE laboratory and clinical
parameters. The role of these receptors in the
pathogenesis of autoimmune diseases has not been
known until now.
It has been shown that mRNA for a soluble form of
VEGFR-1 was generated by the alternative splicing in
human umbilical vein endothelial cells and that
sVEGFR-1, as a competitive inhibitor, was able to
bind all isoforms of VEGF and to inhibit VEGF-
induced endothelial cell proliferation.
13 It has been
suggested that sVEGFR-1 is likely to be a negative
regulator of VEGF availability by sequestering the
ligand and by forming inactive heterodimers with
membrane-bound VEGF receptors. In this way
sVEGFR-1 acts as a specific endogenous antagonist
of its membrane-bound counterparts. VEGFR-2 is
also able to bind VEGF but that receptor ligand
complex formation, in contrast to sVEGFR-1, is
heparin dependent.
16 Based on these findings, the
soluble VEGF receptors may be involved in the
pathophysiology of SLE and their interaction with
VEGF as a potential VEGF inhibitor and that they may
influence the clinical course of SLE and the disease
activity.
In our study we have revealed that the sVEGFR-1
concentration is the highest in active SLE, whereas
levels of this receptor in inactive disease and in
healthy individuals are comparable. To our knowl-
edge soluble receptors of VEGF have not been
previously determined in autoimmune diseases.
However, a higher sVEGFR level has been detected
in serum or plasma of patients with some haemato-
poietic system neoplasms or renal cancer
2628 and
also in healthy people.
29 In up-to-date studies
endothelial cells and monocytes have been found
to be the primary source of sVEGFR-1; however, the
regulation of switching the transcription from the
transmembrane to the soluble form is still not fully
elucidated.
30 Moreover, it has been shown that
hypoxia and also pro-angiogenic cytokines, VEGF
and basic fibroblast growth factor cause up-regula-
tion of sVEGFR-1 expression in endothelial cells.
30,31
The serum level of these angiogenic cytokines in SLE
patients appears to be higher,
21 which might indicate
that they are at least partially responsible for the
increase in sVEGFR-1 serum concentration. More-
over, the sVEGFR-1 and VEGF complex can prolong
the VEGF half-life through prevention of this cyto-
kine proteolysis, lengthening in this way its activity.
17
In our study, however, we have not observed a
positive correlation between VEGF and sVEGFR-1
concentrations.
Contrary to sVEGFR-1, the sVEGFR-2 serum con-
centration in SLE patients was considerably lower
than in healthy controls and did not correlate with the
disease activity. These differences are difficult to
explain. It is, however, known that monocytes/
macrophages express a significant level of VEGFR-1
E. Robak et al.
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32 The
biological activity of sVEGFR-2 is not completely
understood. It has been shown to inhibit corneal
neovascularisation induced by conditional media
from a rat mammary carcinoma cell line.
33 Further-
more, sVEGFR-2 can increase the number of capil-
laries displaying synchronous apoptosis in papillary
membrane explant assay.
34 Yet, the role of this
receptor in SLE and other autoimmune diseases
pathogenesis in vivo requires further investigations.
Differences in biological activity of both receptors
should be emphasised. VEGFR-1 has a more than 10-
fold higher affinity to VEGF-A, even in a soluble
form, but has about a 10-fold lower tyrosine kinase
activity than VEGFR-2.
35 In addition to sequestering
the ligand, sVEGFR-1 can form heterodimers with
transmembrane VEGFR-2, prevent its autophosphor-
ylation and thus abolish signalling in a dominant-
negative fashion.
13 In this context the lack of balance
between sVEGFR-1 and sVEGR-2 in serum of SLE
patients is likely to have a pathogenetic impact and
needs further studies.
In conclusion, in SLE patients the levels of VEGF
and sVEGFR-1 are higher in patients with active SLE
than in inactive disease or healthy persons. In
contrast, sVEGFR-2 is lower in active SLE than in
inactive disease. The imbalance between VEGF and
its soluble receptors may be important in SLE
pathogenesis.
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